

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/089912 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 235/06**,  
401/10, A61K 31/4184, 31/454, 31/496, A61P 21/02,  
23/00, 25/08, 25/20, 25/22

(21) International Application Number:  
PCT/EP2004/050427

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2003 00557 10 April 2003 (10.04.2003) DK  
60/461,794 11 April 2003 (11.04.2003) US

(71) Applicant (for all designated States except US): **NEUROSEARCH A/S** [DK/DK]; 93 Pederstrupvej, DK-2750 Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LARSEN, Janus, S.** [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). **TEUBER, Lene** [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK).

(74) Common Representative: **NEUROSEARCH A/S**; Patent Department, 93 Pederstrupvej, DK-2750 Ballerup (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Published:**

— with international search report

[Continued on next page]

(54) Title: NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS



(57) Abstract: The present invention relates to novel benzimidazole derivatives of the formula (I) as defined in the description and in the claims, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA<sub>A</sub> receptor complex, and in particular for inducing and maintaining anaesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children. The compounds of the invention may also be used by veterinarians.

WO 2004/089912 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

JC20 Rec'd PCT/PTO 30 SEP 2009

**NOVEL BENZIMIDAZOLE DERIVATIVES AND  
PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS**

**TECHNICAL FIELD**

The present invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith.

The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA<sub>A</sub> receptor complex, and in particular for inducing and maintaining anaesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children.

The compounds of the invention may also be used by veterinarians.

**BACKGROUND ART**

Agents that bind or interact with the modulatory sites on the GABA<sub>A</sub> receptor complex, such as for example the benzodiazepine receptor, can have either enhancing effect on the action of GABA, i.e. a positive modulatory effect of the receptor (agonists, partial agonists), an attenuating effect on the action of GABA, i.e. negative modulation of the receptor (inverse agonists, partial inverse agonists), or they can block the effect of both agonists and inverse agonists (antagonists or ligands without intrinsic activity).

Agonists generally produce muscle relaxant, hypnotic, sedative, anxiolytic, and/or anticonvulsant effects, while inverse agonists produce pro-convulsive, anti-inebriant or anxiogenic effects. Compounds with anxiolytic effects, but with or without reduced muscle relaxant, hypnotic and sedative effects, are characterised as partial agonists. Partial inverse agonists are considered to be useful as cognition enhancers.

Full agonists of the benzodiazepine receptor are considered useful as anaesthetics. However, many drugs presently available as anaesthetics, and especially pre-anaesthetics, give rise to hang-over effects as well as long awakening times, wherein careful monitoring of the patient is necessary. Anaesthetics with a long half-life may also impose difficulties during incidents of overdosing i.e. prolonged respiratory depression. Furthermore, some currently used drugs cannot be used for anaesthetising children as deaths have been reported in children after prolonged use of Propofol. Some anaesthetics are gasses, which inherently possesses a contamination problem for the medical staff.

A well known anaesthetic, Propofol, is administered as a mixture of soybean oil, glycerol and purified egg phosphatide, which mixture nourish bacterial growth. Administration of bacterially contaminated Propofol has been reported to cause sepsis and death [Wiklund *et al.*; The New England Journal of Medicine 1997 337 (16) 1132-  
5 1141]. Further, compounds with a long *in vivo* half-life will give problems with accumulation during and after prolonged treatment e.g. when administered to patients constrained to a respirator. Short half-lives wherein the compounds are metabolised to inactive metabolites allow for a predictable correlation of dose and duration of pharmacological effect.

10 Ideally the anaesthetising effect should be observed shortly after a bolus injection or infusion of the compound. A rapid onset of action minimises the period of anxiety and uneasiness experienced by patients going into surgery.

Patients suffering from severe and continuous epileptic attacks presently treated with large amounts of sedatives, e.g. benzodiazepines, will benefit from  
15 shorter acting compounds with no hang-over or long lasting sedating effect.

As the preferred route of administration is by intravenous injection or infusion, the anaesthetising compounds should preferably be water soluble.

EP 616807 describes benzimidazole compounds for use as benzodiazepine receptor ligands.

20 WO 96/33194, WO 96/33191 and WO 96/33192 describe benzimidazole compounds having affinity for the GABA receptor complex.

WO 98/34923 describes phenylbenzimidazole derivatives as ligands for the GABA receptor complex.


WO 98/17651, WO 00/78728 and WO 02/050057 describe benzimidazole  
25 compounds for use as e.g. anaesthetics.

However, there is a continued strong need to find compounds with an optimized pharmacological profile.

#### SUMMARY OF THE INVENTION

30 It is an object of the invention to provide novel compounds useful as anaesthetics and/or pre-anaesthetics, sedatives, muscle relaxants, and for the treatment of febrile convulsions in children, status epilepticus, for use to patients constrained to a respirator as well as for veterinarian uses. A further object of the  
35 invention is to produce compounds which show a rapid onset of action. A still further object of the invention is to produce compounds with less hang-over effect and/or less long lasting sedation effect thereby showing a faster recovery of the patients.

In its first aspect, the invention provides a compound of general formula I:



or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R, R', X, m and n are defined as below.

5        In its second aspect, the invention provides a pharmaceutical composition containing a therapeutically effective amount of a compound according to the invention, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

10       In its third aspect, the invention provides a use of a compound according to the invention, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABA receptor complex.

15       In its fourth aspect, the invention provides a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the GABA receptor complex, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to the invention, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof.


20       Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and the working examples.

## DETAILED DISCLOSURE OF THE INVENTION

25

### Benzimidazole Derivatives

In its first aspect the invention provides novel compounds. The compounds of the invention are represented by general formula I:



or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein  
 R represents alkyl, hydroxyalkyl, alkoxyalkyl,  $R^aR^bN$ -alkyl,  $R^aR^bN$ -CO-alkyl, or phenyl-  
 5 alkyl;  
 wherein  $R^a$  and  $R^b$  independently of each other represents hydrogen or alkyl;  
 $R'$  represents alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, alkylcarbonylalkyl, alkenyl, or  
 alkynyl;  
 m is 0 or 1;  
 10 n is 1 or 2;  
 X represents N or CH.

In one embodiment of the compound general formula I, n is 1 and X  
 represents N.

15 In a second embodiment of the compound of general formula I, n is 1 and X  
 represents CH.

In a further embodiment of the compound of general formula I, R represents  
 alkyl, hydroxyalkyl, or alkoxyalkyl. In a special embodiment, R represents alkyl, such  
 as methyl, ethyl, n-butyl, or iso-butyl. In a further embodiment, R represents  
 20 hydroalkyl, such as hydroxymethyl or hydroxyethyl. In a still further embodiment, R  
 represents alkoxyalkyl. In a special embodiment, R represents alkoxyethyl, such as  
 methoxyethyl.

In a further embodiment of the compound of general formula I, R represents  
 $R^aR^bN$ -alkyl,  $R^aR^bN$ -CO-alkyl, or phenyl-alkyl. In a further embodiment, R represents  
 25  $R^aR^bN$ -alkyl or  $R^aR^bN$ -CO-alkyl, wherein  $R^a$  and  $R^b$  independently of each other  
 represents hydrogen, methyl or ethyl. In a special embodiment, R represents  $R^aR^bN$ -  
 alkyl. In a further embodiment, R represents methylaminoalkyl or dimethylaminoalkyl,  
 such as methylaminoethyl or dimethylaminoethyl. In a still further embodiment, R  
 represents  $R^aR^bN$ -CO-alkyl. In a further embodiment, R represents  
 30 methylcarbamoylealkyl, ethylcarbamoylealkyl, or dimethylcarbamoylealkyl, such as  
 methylcarbamoylemethyl, ethylcarbamoylemethyl or dimethylcarbamoylemethyl. In a still  
 further embodiment, R represents phenyl-alkyl, such as phenylmethyl.

In a further embodiment of the compound of general formula I, R<sup>a</sup> and R<sup>b</sup> independently of each other represents hydrogen, methyl or ethyl. In one embodiment, R<sup>a</sup> represents hydrogen. In a second embodiment, R<sup>a</sup> represents methyl. In a further embodiment, R<sup>a</sup> represents ethyl. In a still further embodiment, R<sup>b</sup> represents hydrogen. In a further embodiment, R<sup>b</sup> represents methyl. In a still further embodiment, R<sup>b</sup> represents ethyl. In a further embodiment, R<sup>a</sup> represents methyl and R<sup>b</sup> represents methyl. In a still further embodiment, R<sup>a</sup> represents methyl and R<sup>b</sup> represents hydrogen. In a further embodiment, R<sup>a</sup> represents ethyl and R<sup>b</sup> represents hydrogen.

10 In a further embodiment of the compound of general formula I, R' represents alkoxyalkyl. In a special embodiment, R' represents alkoxyethyl, such as methoxyethyl or ethoxyethyl. In a further embodiment, R' represents methoxyalkyl. In a still further embodiment, R' represents ethoxyalkyl.

In a further embodiment of the compound of general formula I, R' represents alkylcarbonylalkyl, alkenyl, or alkynyl. In one embodiment, R' represents alkylcarbonylalkyl, such as methylcarbonylalkyl or alkylcarbonylmethyl. In a special embodiment, R' represents methylcarbonylmethyl. In a further embodiment, R' represents alkenyl, such as propenyl. In a special embodiment, R' represents allyl. In a still further embodiment, R' represents alkynyl, such as propynyl. In a special embodiment, R' represents propargyl.

In a still further embodiment of the compound of general formula I, R represents alkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents N.

In a further embodiment of the compound of general formula I, R represents hydroxyalkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents N.

25 In a still further embodiment of the compound of general formula I, R represents alkoxyalkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents N.

In a still further embodiment of the compound of general formula I, R represents alkyl, R' represents alkoxyalkyl, m is 1, n is 1 and X represents N.

In a further embodiment of the compound of general formula I, R represents hydroxyalkyl, R' represents alkoxyalkyl, m is 1, n is 1 and X represents N.

In a still further embodiment of the compound of general formula I, R represents alkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents CH.

In a still further embodiment of the compound of general formula I, R represents alkoxyalkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents CH.

35 In a further embodiment of the compound of general formula I, R represents hydroxyalkyl, R' represents alkynyl, m is 0, n is 1 and X represents N.

In a still further embodiment of the compound of general formula I, R represents alkoxyalkyl, R' represents alkenyl, m is 0, n is 1 and X represents N.

In a further embodiment of the compound of general formula I, R represents alkoxyalkyl, R' represents alkynyl, m is 0, n is 1 and X represents N.

In a still further embodiment of the compound of general formula I, R represents alkoxyalkyl, R' represents alkylcarbonylalkyl, m is 0, n is 1 and X represents N.

In a further embodiment of the compound of general formula I, R represents phenylalkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents N.

In a still further embodiment of the compound of general formula I, R represents R<sup>a</sup>R<sup>b</sup>N-alkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents N.

In a still further embodiment of the compound of general formula I, R represents R<sup>a</sup>R<sup>b</sup>N-CO-alkyl, R' represents alkoxyalkyl, m is 0, n is 1 and X represents N.

In a special embodiment the chemical compound of the invention is

2-Methoxyethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1a);

2-Hydroxyethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1b);

*n*-Butyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1c);

*iso*-Butyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1d);

2-Methoxyethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1e);

2-Hydroxyethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1f);

*n*-Butyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1g);

*iso*-Butyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1h);

5-(methoxycarbonylmethyl) 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole (1i);

5-(2-hydroxyethoxycarbonylmethyl) 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole (1j);

2-Methoxyethyl 1-(3-(4-(propargyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8a);

2-Methoxyethyl 1-(3-(4-(allyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8b);

2-Methoxyethyl 1-(3-(4-(2-oxo-propyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8c);

2-Methoxyethyl 1-(3-(1-methoxyethyl-4-piperidinyl)-phenyl)-benzimidazole-5-carboxylate (8d);



2-Hydroxyethyl 1-(3-(4-(propargyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8e);

Benzyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10a);

5 Methylcarbamoylmethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10b);

Ethylcarbamoylmethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10c);

2-Dimethylaminoethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10d);

10 Benzyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10e);

Methylcarbamoylmethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10f);

15 Ethylcarbamoylmethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10g);

2-Dimethylaminoethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10h);

or an N-oxide thereof, or a pharmaceutically acceptable salt thereof.

20

#### Definition of Substituents

In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to six carbon atoms (C<sub>1-6</sub>-alkyl), including pentyl, isopentyl, 25 neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C<sub>1-4</sub>-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a C<sub>1-3</sub>-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.

In the context of this invention an alkenyl group designates a carbon chain 30 containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C<sub>2-6</sub>-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3-butenyl, or 1,3-butadienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1,3-hexadienyl, or 1,3,5- 35 hexatrienyl.

In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-yne, tri-yne and poly-yne. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C<sub>2-6</sub>-alkynyl), including at least one triple bond. In its most preferred

embodiment the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1,3-butdiynyl; 1-, 2-, 3-, 4-pentynyl, or 1,3-pentdiynyl; 1-, 2-, 3-, 4-, or 5-henynyl, or 1,3-hexdiynyl or 1,3,5-hextriynyl.

Alkoxy means O-alkyl, wherein alkyl is as defined above.

5 Alkoxyalkyl means alkoxy as above and alkyl as above, meaning for example, methoxymethyl.

#### Pharmaceutically Acceptable Salts

The chemical compound of the invention may be provided in any form suitable  
10 for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.

Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the  
15 hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from  
20 ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the lactate derived  
25 from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulphonate derived from methane sulphononic acid, the naphthalene-2-sulphonate derived from naphthalene-2-sulphonic acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived  
30 from stearic acid, the succinate derived from succinic acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphononic acid, and the like. Such salts may be formed by procedures well known and described in the art.

Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as  
35 intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.

Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysine,

and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art.

In the context of this invention the "onium salts" of N-containing compounds  
5 are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.

Examples of pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention  
10 include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.

The chemical compound of the invention may be provided in dissoluble or  
15 indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.

20

#### Steric Isomers

The chemical compounds of the present invention may exist in (+) and (-) forms as well as in racemic forms ( $\pm$ ). The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.

25 Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present  
30 invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example.

The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the  
35 present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphoric acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.

Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by *Jaques J, Collet A, & Wilen S* in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

Optical active compounds can also be prepared from optical active starting  
5 materials.

Moreover, some of the chemical compounds of the invention having an alkenyl group, may exist in two forms, syn- and anti-form (Z- and E-form), depending on the arrangement of the substituents around the -C=C- double bond. A chemical compound of the present invention may thus be the syn- or the anti-form (Z- and E-form), or it may  
10 be a mixture hereof.

#### N-oxides

In the context of this invention an N-oxide designates an oxide derivative of a nitrogen containing compound, e.g. N-containing heterocyclic compounds capable of  
15 forming such N-oxides, and compounds holding one or more amino groups. For example, the N-oxide of a compound containing a pyridyl may be the 1-oxy-pyridin-2-, -3 or -4-yl derivative.

N-oxides of the compounds of the invention may be prepared by oxidation of the corresponding nitrogen base using a conventional oxidizing agent such as  
20 hydrogen peroxide in the presence of an acid such as acetic acid at an elevated temperature, or by reaction with a peracid such as peracetic acid in a suitable solvent, e.g. dichloromethane, ethyl acetate or methyl acetate, or in chloroform or dichloromethane with 3-chloroperoxybenzoic acid.

#### 25 Labelled Compounds

The compounds of the invention may be used in their labelled or unlabelled form. In the context of this invention "label" stands for the binding of a marker to the compound of interest that will allow easy quantitative detection of said compound.

The labelled compounds of the invention may be useful as diagnostic tools,  
30 radio tracers, or monitoring agents in various diagnostic methods, and for *in vivo* receptor imaging.

The labelled isomer of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionuclide is preferably selected from  $^2\text{H}$   
35 (deuterium),  $^3\text{H}$  (tritium),  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{123}\text{I}$ , and  $^{18}\text{F}$ .

The physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS),

Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.

#### Methods of Preparation

- 5       The chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
- 10       Also one compound of the invention can be converted to another compound of the invention using conventional methods.
- The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
- 15       The compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

#### 20 Pharmaceutical Compositions

      In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention.

- While a compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active
- 25   ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.

- In a preferred embodiment, the invention provides pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt or
- 30   derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

- Pharmaceutical compositions of the invention may be those suitable for oral,
- 35   rectal, bronchial, nasal, pulmonary, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.

Suitable examples of sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.

The chemical compound of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof. Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.

The chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.

For preparing pharmaceutical compositions from a chemical compound of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders,

capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed  
5 homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.

Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

10 Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

The chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or  
15 continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in  
20 powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening  
25 agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

30 Also included are solid form preparations, intended for conversion shortly before use to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. In addition to the active component such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

35 For topical administration to the epidermis the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying

agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.

In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.

When desired, compositions adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.



Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g.  $ED_{50}$  and  $LD_{50}$ , may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio  $LD_{50}/ED_{50}$ . Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.

The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.

The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing from about 0.1 to about 500 mg of active ingredient per individual dose, preferably from about 1 to about 100 mg, most preferred from about 1 to about 10 mg, are suitable for therapeutic treatments.

The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1  $\mu\text{g}/\text{kg}$  i.v. and 1  $\mu\text{g}/\text{kg}$  p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1  $\mu\text{g}/\text{kg}$  to about 10 mg/kg/day i.v., and from about 1  $\mu\text{g}/\text{kg}$  to about 100 mg/kg/day p.o.

#### Biological Activity

The compounds of the invention are particularly useful as anaesthetics and/or pre-anaesthetics, for inducing and maintaining anaesthesia, as sedatives, as muscle relaxants, and for combating febrile convulsions in children, status epilepticus, for use to patients constrained to a respirator.

The compounds of the invention show a short duration of action, they are water soluble at therapeutic relevant doses, and are particularly well suited for intravenous administration.

The compounds of the invention may also be used by veterinarians.

The compounds of the invention show high to moderate affinity for the benzodiazepine receptor as measured by displacement at  $^3\text{H}$ -flunitrazepam *in vitro* as well as *in vivo*. The most preferred compounds are full agonists i.e. they exert a high maximal effect in the seizure test as described in the application.

Preferred compounds are full agonists on the GABA<sub>A</sub> receptor complex, e.g. as measured by the anticonvulsant activity in the ptz-test as described in Test method 2.

The compounds of the invention show half-lives of below 30 minutes, which  
5 allows for a short duration of action. Preferred half-lives are in the range of from about 30 seconds to about 20 minutes. Most preferred half-lives are in the range of from about 2 to about 5 minutes.

The preferred compounds induce a rapid onset of anaesthesia, i.e. in less than 1-2 minutes. Most preferred is an onset of anaesthesia in less than 1 minute.

10 Awakening from anaesthesia following a bolus injection (i.v.), or following the attenuation of an infusion, should occur within a short period of time, i.e. of from about 5 to about 30 minutes, preferably of from about 5 to about 10 minutes, after which time the patient should normalise rapidly, i.e. in less than 40 minutes, preferably in less than 20 minutes, as measured from awakening.

15 The compounds of this invention can be used together with analgetic compounds such as Remifentanyl, Fentanyl, or other opioids.

#### Methods of Therapy

In another aspect the invention provides a method for the treatment,  
20 prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of the GABA receptor complex, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of compound according to the invention, or an N-oxide thereof, or a  
25 pharmaceutically acceptable salt thereof.


In a more preferred embodiment the invention provides a method for the induction or maintenance of anaesthesia or pre-anaesthesia, muscle relaxation or sedation, or for the treatment, prevention or alleviation of fewer cramps or status epilepticus.

30 It is at present contemplated that suitable infusion rates are in the range of from about 0.01 to about 100 mg/kg/hour, more preferred of from about 0.1 to about 15 mg/kg/hour, dependent upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and  
35 experience of the physician or veterinarian in charge.

## EXAMPLES


The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

5







**Example 1****Method A:****2a-i****1a-i**

10

The benzimidazoles of Table 1 were all prepared according to the above scheme.

**Table 1**

Comp. No.	R <sub>1</sub>	R <sub>2</sub>	m	Mp (°C)	Yield (%)	Starting material	Salt
1a	MeO(CH <sub>2</sub> ) <sub>2</sub>		0	A	52	2a	HCl
1b	HO(CH <sub>2</sub> ) <sub>2</sub>		0	A	47	2b	HCl
1c	Me(CH <sub>2</sub> ) <sub>3</sub>		0	92-95	54	2c	HCl
1d	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>		0	154-160	58	2d	HCl

Comp. No.	R <sub>1</sub>	R <sub>2</sub>	m	Mp (°C)	Yield (%)	Starting material	Salt
1e	MeO(CH <sub>2</sub> ) <sub>2</sub>		0	173-178	45	2e	HCl
1f	HO(CH <sub>2</sub> ) <sub>2</sub>		0	159-162	38	2f	HCl
1g	Me(CH <sub>2</sub> ) <sub>3</sub>		0	148-152	59	2g	HCl
1h	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>		0	159-163	25	2h	HCl
1i	Me		1	A	60	2i	-
1j	HO(CH <sub>2</sub> ) <sub>2</sub>		1	A	88	1i	HCl

The yield is given for a total of 3 steps starting from 4a-b and 5a-e. A few of these compounds were hygroscopic solids, therefore no melting points were recorded. Instead these compounds were verified by exact mass determination. Results are given for compounds 1a, b, i and j below.

General procedure for the preparation of 1a-i:

A mixture of 2a-i 1 eqv., triethylorthoformate 2 eqv. and a catalytic amount of p-toluenesulfonic acid in tetrahydrofuran (10 ml) was heated to reflux for 30 min. The cooled mixture was evaporated in vacuo, then dissolved in ethyl acetate and washed with sat. NaHCO<sub>3</sub> aq.. The organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel using CH<sub>2</sub>Cl<sub>2</sub> / MeOH / NH<sub>3</sub>aq. (9:1:1%) as an eluent. The collected fractions were evaporated to give the desired product as a free base. Subsequently, the product was precipitated from THF as the hydrochloride by addition of a 1M ethereal hydrogen chloride to the solution.

The following compounds were prepared in analogy with the above procedure:

2-Methoxyethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-

20 carboxylate (1a). Calc: C<sub>25</sub>H<sub>33</sub>N<sub>4</sub>O<sub>4</sub> (M+H<sup>+</sup>) = 453.2502. Found: C<sub>25</sub>H<sub>33</sub>N<sub>4</sub>O<sub>4</sub> (M+H<sup>+</sup>) = 453.2499.

2-Hydroxyethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-

25 carboxylate (1b). Calc: C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> (M+H<sup>+</sup>) = 439.2345. Found: C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> (M+H<sup>+</sup>) = 439.2348.

*n*-Butyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1c).

Isobutyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1d).

2-Methoxyethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1e).


2-Hydroxyethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-  
10 carboxylate (1f).

***n*-Butyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1g).**

15 **iso-Butyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate**  
**(1h).**

5-(methoxycarbonylmethyl) 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole (11). Calc:  $C_{23}H_{28}N_4O_3$  ( $M+H^+$ ) = 409.2240. Found:  $C_{23}H_{28}N_4O_3$  ( $M+H^+$ ) = 409.2222.

5-(2-hydroxyethoxycarbonylmethyl) 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole (1j): This compound was prepared from **1i** by transesterification. 0.2 g of **1i** was dissolved in 5 ml ethyleneglycol and heated to 100°C overnight. The resulting cooled mixture was taken up in EtOAc and washed with H<sub>2</sub>O. The organic phase was dried MgSO<sub>4</sub> and evaporated in vacuo. The compound was purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3</sub>aq. (9:1:1%) as an eluent. The product was dissolved in THF and an ethereal solution of hydrochloric acid was added. The resulting hydrochloride of **1j** was filtered off. Yield: 85%. Calc: C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> (M+H<sup>+</sup>) = 439.2345. Found: C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> (M+H<sup>+</sup>) = 439.2363.



The diamines of Table 2 were all prepared quantitatively by hydrogenation of the corresponding nitroanilines (3), according to the above scheme.




Table 2

5

Comp. No.	R <sub>1</sub>	R <sub>2</sub>	m	Starting material
2a	MeO(CH <sub>2</sub> ) <sub>2</sub>		0	3a
2b	HO(CH <sub>2</sub> ) <sub>2</sub>		0	3b
2c	Me(CH <sub>2</sub> ) <sub>3</sub>		0	3c
2d	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>		0	3d
2e	MeO(CH <sub>2</sub> ) <sub>2</sub>		0	3e
2f	HO(CH <sub>2</sub> ) <sub>2</sub>		0	3f
2g	Me(CH <sub>2</sub> ) <sub>3</sub>		0	3g
2h	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>		0	3h
2i	Me		1	3i

General procedure for the hydrogenation of 3a-i:

3a-i was suspended in tetrahydrofurane. Palladium catalyst (50 mg, 5% on activated carbon) was added and the mixture was hydrogenated at ambient pressure until the hydrogen uptake had ceased. The mixture was filtered through celite and the filtrate was evaporated to dryness to leave 2a-i, quantitatively.

The following compounds were prepared in according to the above mentioned procedure.

5 2-Methoxyethyl 3-amino-4-(3-((1-ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
(2a).

2-Hydroxyethyl 3-amino-4-(3-(1-(ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
(2b).

10 *n*-Butyl 3-amino-4-(3-((1-ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2c).

*iso*-Butyl 3-amino-4-(3-((1-ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2d).


15 2-Methoxyethyl 3-amino-4-(3-((1-methoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
(2e).

2-Hydroxyethyl 3-amino-4-(3-(1-(methoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
(2f).

20 *n*-Butyl 3-amino-4-(3-((1-methoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2g).

*iso*-Butyl 3-amino-4-(3-((1-methoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2h).

25 5-Methoxycarbonylmethyl 2-(3-((1-methoxyethyl-4-piperazinyl)-phenylamino)-aniline  
(2i).



The nitroanilines of Table 3 were prepared by reaction of 4-chloro-3-  
30 nitrobenzoates 5 with substituted anilines (4), according to the above scheme.




Table 3

Comp. No.	R <sub>1</sub>	R <sub>2</sub>	m	Starting material
3a	MeO(CH <sub>2</sub> ) <sub>2</sub>		0	4a, 5a
3b	HO(CH <sub>2</sub> ) <sub>2</sub>		0	4a, 5b
3c	Me(CH <sub>2</sub> ) <sub>3</sub>		0	4a, 5c
3d	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>		0	4a, 5d
3e	MeO(CH <sub>2</sub> ) <sub>2</sub>		0	4b, 5a
3f	HO(CH <sub>2</sub> ) <sub>2</sub>		0	4b, 5b
3g	Me(CH <sub>2</sub> ) <sub>3</sub>		0	4b, 5c
3h	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>		0	4b, 5d
3i	Me		1	4b, 5e

5

General procedure for the preparation of compounds 3a-i:

A mixture of 5a-a 1 eqv., 4a-b 1 eqv. and triethylamine 1 eqv. in NMP (10 ml) was heated to 110°C overnight. The cooled mixture was partitioned between water and ethyl acetate. The phases were separated and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:1 v/v) as the eluent.

10



The following compounds were prepared in analogy with the above-mentioned procedure.

2-Methoxyethyl 3-nitro-4-(3-(1-(ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
5 (3a).

2-Hydroxyethyl 3-nitro-4-(3-(1-(ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
(2b).

10 *n*-Butyl 3-nitro-4-(3-(1-(ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2c)

*iso*-Butyl 3-nitro-4-(3-(1-(ethoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2d)


2-Methoxyethyl 3-nitro-4-(3-(1-(methoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
15 (2e).

2-Hydroxyethyl 3-nitro-4-(3-(1-(methoxyethyl-4-piperazinyl)-phenylamino)-benzoate  
(2f).

20 *n*-Butyl 3-nitro-4-(3-(1-(methoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2g).

*iso*-Butyl 3-nitro-4-(3-(1-(methoxyethyl-4-piperazinyl)-phenylamino)-benzoate (2h).

5-Methoxycarbonylmethyl 2-(3-(1-(methoxyethyl-4-piperazinyl)-phenylamino)-  
25 nitrobenzene (2i).



The substituted anilines of Table 4 were prepared by hydrogenation of the  
30 corresponding nitro compounds 6a-b as exemplified by compound 4a below.




Table 4

Comp. No.	R <sub>2</sub>	Starting material
4a		6a
4b		6b

General procedure for the hydrogenation of compounds 6a-b:

5 To a solution of 6a or 6b in abs. ethanol (50 ml) was added palladium catalyst (100 mg, 5% Pd on activated carbon) and the mixture was hydrogenated at ambient pressure until the hydrogen uptake had ceased. Filtration through celite and evaporation of solvent left 4a or 4b, quantitatively.

10 The following compounds were prepared according to the above mentioned procedure:

1-Ethoxyethyl-4-(3-aminophenyl)-piperazine (4a).

15 1-Methoxyethyl-4-(3-aminophenyl)-piperazine (4b).

The 3-nitro-4-chlorobenzoic acid esters 5a-d were prepared by esterification of the corresponding benzoic acids by the method mentioned below.




Table 5

Comp No.	R <sub>1</sub>	m	Yield %	X	Starting material
5a	MeO(CH <sub>2</sub> ) <sub>2</sub>	0	62	Cl	4-chloro-3-nitrobenzoic acid
5b	HO(CH <sub>2</sub> ) <sub>2</sub>	0	88	Cl	4-chloro-3-nitrobenzoic acid
5c	Me(CH <sub>2</sub> ) <sub>3</sub>	0	96	Cl	4-chloro-3-nitrobenzoic acid

25

Comp No.	R <sub>1</sub>	m	Yield %	X	Starting material
5d	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub>	0	95	Cl	4-chloro-3-nitrobenzoic acid
5e	Me	1	55	F	4-fluorophenylacetic acid

General procedure for the preparation of 5a-d:

A mixture of acid (10g) and thionylchloride (50 ml) was heated to reflux overnight. The excess of thionylchloride was removed by evaporation and alcohol (50 ml) was added. The resulting mixture was stirred at 80°C for 4 hours. The cooled solution was diluted with water (500 ml) and extracted with ethyl acetate (2 × 100 ml). The organic extract was washed with NaHCO<sub>3</sub> sat. and dried over magnesium sulphate and concentrated under reduced pressure. This gave the corresponding esters of a relatively high purity.

The following compounds were prepared according to the above mentioned procedure:

2-Methoxyethyl 4-chloro-3-nitrobenzoate (5a).

2-Hydroxyethyl 4-chloro-3-nitrobenzoate (5b).


n-Butyl 4-chloro-3-nitrobenzoate (5c).

iso-Butyl 4-chloro-3-nitrobenzoate (5d).

Methoxycarbonylmethyl-4-chloro-3-nitrobenzene (5e)


4-fluorophenylacetic acid (6g, 38.9 mmol) was suspended in 50 ml H<sub>2</sub>SO<sub>4</sub> conc. And cooled to 0°C. To this suspension was added dropwise 1.75 ml HNO<sub>3</sub> during 30 min. and then the reaction mixture was stirred at 0°C for another 3h. The yellow mixture was poured into is-water and the corresponding white crystals 4-fluoro-3-nitrophenylacetic acid 4.55g, 59% was collected and dried.

4-fluoro-3-nitrophenylacetic acid (4.55g, 22.9 mmol) was suspended in 50 ml MeOH and added 0.15 ml H<sub>2</sub>SO<sub>4</sub> followed by reflux for 2h. After cooling the reaction mixture was poured into water and then added NaHCO<sub>3</sub> until pH>7. The extraction with EtOAc, drying with MgSO<sub>4</sub> and evaporation in vacuo gave 5e. Yield 4.25g, 87%.



#### 1-(3-Nitrophenyl)-piperazine

A suspension of 3-fluoronitrobenzene (23 ml; 0.21 mol) and piperazine (55.5 g; 0.64 mol) in anhydrous NMP (30 ml) was heated to  $70^\circ\text{C}$  for five days. The cooled mixture was diluted with water (250 ml) and extracted with dichloromethane. The combined extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel eluting subsequently with mixtures of ethyl acetate and methanol (4:1 v/v) and (1:1 v/v) to leave the desired product as oily crystals (30.7 g; 71%).



6a

#### Ethoxyethyl 2-(4-(3-nitrophenyl)-1-piperazinyl) (6a)

To a suspension of 1-(3-nitrophenyl)piperazine (8.18 g; 33.7 mmol) in DMF (80 ml) was added triethylamine (9.9 ml; 70.7 mmol) and the reaction was allowed to stir at RT for 30 min. Then bromoethylethyl ether (6 ml; 50 mmol) was added, the mixture was stirred at ambient temperature for 2h. the reaction was worked up by evaporating DMF followed by resuspension in EtOAc and washing with  $\text{NaHCO}_3$  sat. The organic phase was dried and evaporated to give a yellowish oil. This was purified by column chromatography on silica gel using  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  (8:2) as an eluent. Yield of 6a (7.5 g; 81%).

The following compounds were prepared in analogy with Compound 6a:

Methoxyethyl 2-(4-(3-nitrophenyl)-1-piperazinyl) (6b) Yield 78%.


**Example 2****Method B**

The following compounds were synthesised according to the method mentioned below.

5 Compound **7a** was synthesised from 2-Methoxyethyl 1-(3-(4-methoxycarbonylmethyl-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate by dealkylation of the piperazine ring using the method by Kondo *et al*, J. Med. Chem., **1989**, 32 (3), 679-682. 2-Methoxyethyl 1-(3-(4-methoxycarbonylmethyl-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate was synthesised according to International Patent

10 Publication No. WO 00/78728, example 1b.

In the same way compound **7b** was synthesised by dealkylation of 2-methoxyethyl 1-(3-(1-methoxycarbonylmethyl-4-piperidiny1)-phenyl)-benzimidazole-5-carboxylate using the same literature method as mentioned for **7a**. 2-methoxyethyl 1-(3-(1-methoxycarbonylmethyl-4-piperidiny1)-phenyl)-benzimidazole-5-carboxylate was  
 15 synthesised according to International Patent Publication No. WO 02/050057, Example 1d.

20 **Table 6**

Compound nr.	R <sub>1</sub>	R <sub>2</sub>	X	Yield	Starting material	Salt
<b>8a</b>	MeO(CH <sub>2</sub> ) <sub>2</sub>		N	78	<b>7a</b>	formate
<b>8b</b>	MeO(CH <sub>2</sub> ) <sub>2</sub>		N	56	<b>7a</b>	formate
<b>8c</b>	MeO(CH <sub>2</sub> ) <sub>2</sub>		N	50	<b>7a</b>	formate
<b>8d</b>	MeO(CH <sub>2</sub> ) <sub>2</sub>		C	43	<b>7b</b>	formate
<b>8e</b>	HO(CH <sub>2</sub> ) <sub>2</sub>		N	93	<b>8a</b>	HCl

General procedure for the preparation of compounds 8a-d:

To a solution of **7a** or **7b** in  $\text{CH}_2\text{Cl}_2$  was added triethylamine 2 eqv. Followed by 2 eq. of  $\text{R}_2\text{Cl}$ . And stirring was maintained overnight at ambient temperature. The organic phase was washed with water, dried ( $\text{MgSO}_4$ ) and concentrated *in vacuo*. The crude products were purified by preparative LCMS using a gradient 20% B to 95% B in 13 min. A) 5mM  $(\text{NH}_4)\text{HCO}_3/\text{H}_2\text{O}$  B) Acetonitrile. The collected fractions were pooled and acidified with formic acid before evaporation of the solvent. This gave **8a-c** as white solids.

The following compounds were prepared by the above-mentioned method:

2-Methoxyethyl 1-(3-(4-(propargyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8a). Calc:  $\text{C}_{24}\text{H}_{27}\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}^+$ ) = 419.2083. Found:  $\text{C}_{24}\text{H}_{27}\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}^+$ ) = 419.2080.

2-Methoxyethyl 1-(3-(4-(allyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8b).

Calc:  $\text{C}_{24}\text{H}_{29}\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}^+$ ) = 421.2240. Found:  $\text{C}_{24}\text{H}_{29}\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}^+$ ) = 421.2260.

2-Methoxyethyl 1-(3-(4-(2-oxo-propyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8c). Calc:  $\text{C}_{24}\text{H}_{29}\text{N}_4\text{O}_4$  ( $\text{M}+\text{H}^+$ ) = 437.2189. Found:  $\text{C}_{24}\text{H}_{29}\text{N}_4\text{O}_4$  ( $\text{M}+\text{H}^+$ ) = 437.2168.

2-Methoxyethyl 1-(3-(1-methoxyethyl-4-piperidinyl)-phenyl)-benzimidazole-5-carboxylate (8d). Calc:  $\text{C}_{25}\text{H}_{32}\text{N}_3\text{O}_4$  ( $\text{M}+\text{H}^+$ ) = 438.2393. Found:  $\text{C}_{25}\text{H}_{32}\text{N}_3\text{O}_4$  ( $\text{M}+\text{H}^+$ ) = 438.2382.

2-Hydroxyethyl 1-(3-(4-(propargyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8e). This compound was prepared from **8a** by transesterification using the same method as mentioned earlier for compound **1j**. Calc:  $\text{C}_{23}\text{H}_{25}\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}^+$ ) = 405.1927. Found:  $\text{C}_{23}\text{H}_{25}\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}^+$ ) = 405.1927.

29

**Example 3**  
**Method C**




Table 7

5

Compound No.	R <sub>1</sub>	R <sub>2</sub>	Yield %	Starting material	Salt
10a	PhCH <sub>2</sub>		42	9a	HCl
10b	MeNHCOCH <sub>2</sub>		25	9a	HCl
10c	EtNHCOCH <sub>2</sub>		50	9a	HCl
10d	Me <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>		80	9a	HCl
10e	PhCH <sub>2</sub>		53	9b	-
10f	MeNHCOCH <sub>2</sub>		48	9b	HCl
10g	EtNHCOCH <sub>2</sub>		62	9b	HCl
10h	Me <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>		76	9b	HCl

General procedure for the preparation of compounds 9a and 9b:

Compound 1a or 1e was hydrolysed by dissolving the compound in 4M HCl and refluxed overnight. The reaction mixture was then cooled and evaporated in vacuo to give the crude acids 9a and 9b, respectively. No further purification was attempted at this point but the crude reaction mixture was used directly in the next step.

General procedure for the preparation of compounds 10a-h:

The crude acid **9a** or **9b** was dissolved in acetonitrile / DMF 4:1 and then added triethylamine in excess (>3eq) and a small catalytic amount of NaI. The reaction mixture was stirred for 15 min after which the  $R_1Cl$  (2-3 eq.) was added and the reaction was then heated to 60°C overnight. After cooling the acetonitrile was evaporated and the resulting mixture was taken up in DCM and washed with water. The organic phase was dried  $MgSO_4$  and evaporated give oily products. Column chromatography on silica gel using  $CH_2Cl_2$ / MeOH/  $NH_3$ aq. (9:1:1%) as an eluent gave the pure compounds **10a-h**.

The following compounds were prepared using the above method:

Benzyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10a**).

15 Calc:  $C_{28}H_{33}N_4O_3$  ( $M+H^+$ ) = 485.2553. Found:  $C_{28}H_{33}N_4O_3$  ( $M+H^+$ ) = 485.2549.

Methylcarbamoylmethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10b**). Calc:  $C_{25}H_{35}N_5O_4$  ( $M+H^+$ ) = 466.2454. Found:  $C_{25}H_{35}N_5O_4$  ( $M+H^+$ ) = 466.2445.

20 Ethylcarbamoylmethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10c**). Mp. 153-154°C.

2-Dimethylaminoethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10d**). Calc:  $C_{26}H_{38}N_5O_3$  ( $M+H^+$ ) = 466.2818. Found:  $C_{26}H_{38}N_5O_3$  ( $M+H^+$ ) = 466.2811.

Benzyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10e**). Mp. 63°C.

30 Methylcarbamoylmethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10f**). Calc:  $C_{24}H_{30}N_5O_4$  ( $M+H^+$ ) = 452.2298. Found:  $C_{24}H_{30}N_5O_4$  ( $M+H^+$ ) = 452.2286.

35 Ethylcarbamoylmethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10g**). Calc:  $C_{25}H_{32}N_5O_4$  ( $M+H^+$ ) = 466.2454. Found:  $C_{25}H_{32}N_5O_4$  ( $M+H^+$ ) = 466.2459.

40 2-Dimethylaminoethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10h**). Calc:  $C_{25}H_{34}N_5O_3$  ( $M+H^+$ ) = 452.2552. Found:  $C_{25}H_{34}N_5O_3$  ( $M+H^+$ ) = 452.2646.



## TEST METHODS

## Test method 1

*In vitro* and *in vivo* Binding Activity

- 5 The GABA recognition site and the benzodiazepine modulatory unit can selectively be labelled with  $^3\text{H}$ -muscimol and  $^3\text{H}$ -flunitrazepam, respectively.

1A: *In vitro* inhibition of  $^3\text{H}$ -flunitrazepam ( $^3\text{H}$ -FNM) binding10 Tissue Preparation

Preparations are performed at 0-4°C unless otherwise indicated. Cerebral cortex from male Wistar rats (150-200 g) is homogenised for 5-10 sec in 20 ml Tris-HCl (30 mM, pH 7.4) using an Ultra-Turrax homogeniser. The suspension is centrifuged at 27,000 x g for 15 min and the pellet is washed three times with buffer (centrifuged at 27,000 x g for 10 min). The washed pellet is homogenized in 20 ml of buffer and incubated on a water bath (37°C) for 30 min to remove endogenous GABA and then centrifuged for 10 min at 27,000 x g. The pellet is then homogenized in buffer and centrifuged for 10 min at 27,000 x g. The final pellet is resuspended in 30 ml buffer and the preparation is frozen and stored at -20°C.

20

Assay

The membrane preparation is thawed and centrifuged at 2°C for 10 min at 27,000 x g. The pellet is washed twice with 20 ml 50 mM Tris-citrate, pH 7.1 using an Ultra-Turrax homogeniser and centrifuged for 10 min at 27,000 x g. The final pellet is resuspended in 50 mM Tris-citrate, pH 7.1 (500 ml buffer per g of original tissue), and then used for binding assays. Aliquots of 0.5 ml tissue are added to 25 µl of test solution and 25 µl of  $^3\text{H}$ -FNM (1 nM, final concentration), mixed and incubated for 40 min at 2°C. Non-specific binding is determined using Clonazepam (1 µM, final concentration). After incubation the samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fibre filters under suction and immediately washed with 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

35 Results

25-75% inhibition of specific binding must be obtained, before calculation of an  $\text{IC}_{50}$ . The test value will be given as  $\text{IC}_{50}$  (the concentration (µM) of the test substance which inhibits the specific binding of  $^3\text{H}$ -FNM by 50%).

32

$$IC_{50} = (\text{applied test substance concentration, } \mu\text{M}) \times \frac{1}{\left(\frac{C_o}{C_x} - 1\right)}$$

where

$C_o$  is specific binding in control assays, and

5  $C_x$  is the specific binding in the test assay.

(The calculations assume normal mass-action kinetics).

#### 1B: *In vivo* inhibition of $^3\text{H}$ -FNM binding

##### 10 Introduction

*In vitro* binding studies have demonstrated that the benzodiazepine  $^3\text{H}$ -FNM binds selectively and with high-affinity to the GABA<sub>A</sub> receptor-ion channel complex.  $^3\text{H}$ -FNM can also be used for *in vivo* receptor labelling studies in mouse. Accumulation of  $^3\text{H}$ -FNM binding will occur all over the brain as GABA<sub>A</sub> receptors are widely distributed.

15 The specific binding of  $^3\text{H}$ -FNM can be partly or completely prevented by simultaneous or prior administration of pharmacologically active benzodiazepines or by some benzodiazepine-like compounds.

##### Method

20 All test substances used are solutions prepared in 10% TWEEN 80. Groups of three female NMRI mice (25 g) are injected i.v. via the tail vein with 5.0  $\mu\text{Ci}$  of  $^3\text{H}$ -FNM in 0.2 ml saline. Fifteen min after injection with  $^3\text{H}$ -FNM the test substance is administered i.v. Twenty min after injection with  $^3\text{H}$ -FNM, mice are killed by decapitation, the forebrains rapidly excised and homogenized in 12 ml of ice-cold 50 mM Tris-citrate, pH 7.1 using  
25 an Ultra-Turrax homogenizer. Three aliquots of 1 ml are immediately filtered through GF/C glass fibre filters and washed with 2  $\times$  5 ml of ice-cold buffer. The amounts of radioactivity on the filters and in 200  $\mu\text{l}$  of the homogenate are determined by conventional scintillation counting. Groups of untreated mice serves as controls. To determine non-specific binding groups of mice are injected with Clonazepam (25 mg/kg)  
30 i.p. 10 min before  $^3\text{H}$ -FNM injection. Specific binding is the amount of binding in controls minus the amount of binding in Clonazepam treated mice.

##### Results

The  $\text{ED}_{50}$  value is determined from dose response curves. If only one dose of test  
35 substance is administered, the  $\text{ED}_{50}$  value is calculated as follows, provided that the inhibition of specific binding is within the range of 25-75%.

33

$$ED_{50} = (\text{administered dose, mg/kg}) \times \frac{1}{\left(\frac{C_o}{C_x} - 1\right)}$$

where  $C_o$  is specific binding in controls and  $C_x$  is the specific binding in mice treated with test substance.

5

#### Test method 2

##### PTZ Clonic Convulsions

The purpose of this test is to show antagonism of clonic convulsions induced by pentylenetetrazol (PTZ). PTZ induces clonic convulsions in mice after i.v. infusion.

10 Antagonism of PTZ-induced convulsions is a measure for the agonistic character of ligands for the benzodiazepine recognition site.

##### Procedure

Female NMRI mice (Bomholdtgaard, Ry), 20 g, 6 mice in each group are  
15 administered i.v. with vehicle or test substance. After five minutes the PTZ-solution is infused intravenously at a speed of 0.7 ml/minute through a cannula placed in the tail vein. The time from initiation of the infusion to appearance of clonic convulsions is recorded.

The dose of PTZ required for inducing convulsion in each mouse is calculated  
20 as PTZ/kg body weight. Means  $\pm$ sd for each experimental group of 6 mice is calculated.  $ED_{100}$  is calculated by linear regression expressing the dose increasing the PTZ threshold to 100 mg PTZ/kg.

The threshold of vehicle treated controls is in the range of 37-39 mg PTZ/kg. As a control in each series of experiments PTZ is infused into 6 vehicle treated mice.

25

#### Test method 3

##### Evaluation of Efficacy


Selected compounds exhibiting a promising profile in the above tests may be evaluated with respect to efficacy and duration of action and compared to prior art as  
30 follows.

Aqueous solutions of the test substances (50 mg/ml isotonic glucose) are administered to pigs (25-30 kg) as bolus injections. The pigs are observed with respect to the time of induction of anaesthesia, the duration of anaesthesia and the normalising time following awakening from anaesthesia.

35

## Claims

1. A compound of general formula I:



- 5 or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R represents alkyl, hydroxyalkyl, alkoxyalkyl,  $R^aR^bN$ -alkyl,  $R^aR^bN$ -CO-alkyl, or phenyl-alkyl;  
 wherein  $R^a$  and  $R^b$  independently of each other represents hydrogen or alkyl;
- 10  $R'$  represents alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, alkylcarbonylalkyl, alkenyl, or alkynyl;  
 $m$  is 0 or 1;  
 $n$  is 1 or 2;  
 $X$  represents N or CH.
- 15 2. The compound of claim 1, wherein  $n$  is 1 and  $X$  represents N.
3. The compound of claim 1, wherein  $n$  is 1 and  $X$  represents CH.
- 20 4. The compound of any one of claims 1-3, wherein R represents alkyl, hydroxyalkyl, or alkoxyalkyl.
- 25 5. The compound of any one of claims 1-3, wherein R represents  $R^aR^bN$ -alkyl,  $R^aR^bN$ -CO-alkyl, or phenyl-alkyl;  
 wherein  $R^a$  and  $R^b$  independently of each other represents hydrogen, methyl or ethyl.
- 30 6. The compound of any one of claims 1-5, wherein  $R'$  represents alkoxyalkyl.

7. The compound of any one of claims 1-5, wherein  
R' represents alkylcarbonylalkyl, alkenyl, or alkynyl.
8. The compound of claim 1, which is
- 5 2-Methoxyethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1a);  
2-Hydroxyethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1b);  
10 *n*-Butyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1c);  
*iso*-Butyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1d);  
2-Methoxyethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1e);  
15 2-Hydroxyethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1f);  
*n*-Butyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1g);  
*iso*-Butyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (1h);  
20 5-(methoxycarbonylmethyl) 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole (1i);  
5-(2-hydroxyethoxycarbonylmethyl) 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole (1j);  
25 2-Methoxyethyl 1-(3-(4-(propargyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8a);  
2-Methoxyethyl 1-(3-(4-(allyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8b);  
2-Methoxyethyl 1-(3-(4-(2-oxo-propyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8c);  
30 2-Methoxyethyl 1-(3-(1-methoxyethyl-4-piperidinyl)-phenyl)-benzimidazole-5-carboxylate (8d);  
2-Hydroxyethyl 1-(3-(4-(propargyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (8e);  
35 Benzyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10a);  
Methylcarbamoymethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (10b);

Ethylcarbamoylmethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10c**);

2-Dimethylaminoethyl 1-(3-(4-(ethoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10d**);

5 Benzyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10e**);

Methylcarbamoylmethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10f**);

10 Ethylcarbamoylmethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10g**);

2-Dimethylaminoethyl 1-(3-(4-(methoxyethyl)-1-piperazinyl)-phenyl)-benzimidazole-5-carboxylate (**10h**);

or a pharmaceutically acceptable salt thereof.

15 9. A pharmaceutical composition containing a therapeutically effective amount of a compound according to any one of claims 1-8, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

20 10. The use of a compound according to any one of claims 1-8, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABA receptor complex.

25 11. The use according to claim 10, wherein the medicament is for inducing anaesthesia, pre-anaesthesia, muscle relaxation, or sedation, or for treatment, prevention or alleviation of fewer cramps or status epilepticus.

30 12. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the GABA receptor complex, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of claims 1-8, or  
35 an N-oxide thereof, or a pharmaceutically acceptable salt thereof.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/050427

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D235/06 C07D401/10 A61K31/4184 A61K31/454 A61K31/496  
A61P21/02 A61P23/00 A61P25/08 A61P25/20 A61P25/22

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/50057 A (TEUBER LENE ; WAETJEN FRANK (DK); NEUROSEARCH AS (DK)) 27 June 2002 (2002-06-27) page 2, line 24 - page 6, line 22; claims 1-11; example 1; table 1 examples 7-9	1-12
X	WO 00/78728 A (TEUBER LENE ; WAETJEN FRANK (DK); NEUROSEARCH AS (DK)) 28 December 2000 (2000-12-28) page 2, line 28 - page 21, line 39; claims 1-22; examples 1,11,12; table 1 example 13; tables 8-10	1-12
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* & \* document member of the same patent family

Date of the actual completion of the international search

9 August 2004

Date of mailing of the international search report

20/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Papathoma, S

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/050427

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98/17651 A (TEUBER LENE ; WAETJEN FRANK (DK); NEUROSEARCH AS (DK))  30 April 1998 (1998-04-30)  page 2, line 18 - page 17, line 18; claims 1-15; examples 12,12A,12B,16-22,24,25;  table 4  examples 37,38; table 7  -----</p>	1-12



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/050427

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0250057	A	27-06-2002	AU 2156602 A WO 0250057 A1	01-07-2002 27-06-2002
WO 0078728	A	28-12-2000	AU 5391000 A BR 0011823 A CA 2373921 A1 CN 1356987 T WO 0078728 A1 EP 1194410 A1 JP 2003502405 T NZ 515543 A US 2003055055 A1 US 2004097570 A1	09-01-2001 19-03-2002 28-12-2000 03-07-2002 28-12-2000 10-04-2002 21-01-2003 28-11-2003 20-03-2003 20-05-2004
WO 9817651	A	30-04-1998	AU 726447 B2 AU 4616197 A CA 2267114 A1 CN 1234025 A ,B CZ 9901272 A3 WO 9817651 A1 EP 0934281 A1 JP 2001502675 T NZ 334868 A RU 2194699 C2 SK 42499 A3 US 6218547 B1 US 2003166638 A1 US 6503925 B1	09-11-2000 15-05-1998 30-04-1998 03-11-1999 15-09-1999 30-04-1998 11-08-1999 27-02-2001 23-02-2001 20-12-2002 16-05-2000 17-04-2001 04-09-2003 07-01-2003